Category Archives: Health

What is new in the field of Health. Trending topics, and cutting edge research in the are of Health. Press Releases that give us updates on Health.

Health

Greenlight Guru Releases The AI in MedTech Trend Report 2023

Leave a comment


  • Just 32% of respondents use AI tools in their day-to-day work, yet 85% were interested in exploring AI applications further.
  • AI adoption varies by role: Manufacturing & Operations (50%), Clinical roles (40%), and Quality & Regulatory Affairs (28%).
  • Over 80% of respondents are using ChatGPT. Other popular tools include Bard, Fireflies, and Midjourney.
  • Respondents cited concerns about the accuracy of data or answers, decision-making errors, and potential regulatory, privacy, and cybersecurity issues.

“What the Trend Report tells us is that there is tremendous interest in AI tools in the MedTech space, but that interest is tempered by concerns about data accuracy, especially when it comes to making key decisions based on AI outputs,” said Tyler Foxworthy, Chief Data Scientist at Greenlight Guru. “The industry needs more MedTech-specific AI tools they can trust both for patient safety and regulatory purposes.”

The Trend Report is part of Greenlight Guru’s larger push to integrate the power of AI into the MedTech space. In May of 2023, the company released Risk Intelligence, which helps users identify and assess the most relevant risks for their devices using AI and advanced statistical models powered by real-world data. The forthcoming Digital Guru, currently in Beta testing, is the only chat solution specifically trained on MedTech industry regulations, requirements, and best practices, and specifically tailored for MedTech companies. This solution will enable MedTech professionals to get instant and accurate answers to commonly asked questions about a range of industry topics, from product risk profiles to regulatory changes.

“Our focus has always been on helping the MedTech industry deliver safe and innovative products that will improve the quality of life for patients around the world,” said David DeRam, CEO of Greenlight Guru. “As we continue to add AI applications to our products and develop new solutions, that focus will help ensure that our customers and the patients they serve are at the forefront of everything we do. The Trend Report confirms that the demand for AI tools is high, but so is the bar we’ve set for quality in the MedTech industry.”

For a closer look at the findings, you can find the full AI in MedTech Trend Report 2023 here.

Greenlight Guru will host a free virtual event covering AI in MedTech on December 7, which will include an in-depth presentation on the report findings. More information and event sign-up can be found here.

About Greenlight Guru
Greenlight Guru is the leading connected, cloud-based platform purpose-built for MedTech companies. The end-to-end solution streamlines product development, quality management, and clinical data management by integrating cross-functional teams, processes, and data throughout the entire product lifecycle. Greenlight Guru’s platform is used by organizations across the globe that are replacing their disjointed, legacy tools and solutions to bring life-changing products to people faster and with less risk. For more information, visit https://www.greenlight.guru.

Media Contact

PR at Greenlight Guru, Greenlight Guru, (317) 960-4220, [email protected], https://www.greenlight.guru/

SOURCE Greenlight Guru

Lifestyle: Self Help

Freshpaint Unveils Healthcare Privacy Platform Empowering Privacy-First Marketing That Ensures HIPAA Compliance

Leave a comment


With a dedicated privacy platform, healthcare organizations will be in compliance with HIPAA through technology that allows them to understand and govern the data shared to third-party tools. The Freshpaint Healthcare Privacy Platform includes:

  • Embedded video support: Allows healthcare organizations to use tools like YouTube on websites, while ensuring HIPAA compliance.
  • Web tracker monitoring: Gives marketers visibility into all third-party web trackers that may be running on websites and other digital platforms. With this information at their fingertips, companies can swiftly identify and address any potential privacy risks, ensuring patient data remains protected at all times.
  • Data governance verification: Gives healthcare organizations a clear picture of exactly what data is being shared to end destinations. This transparency not only builds trust but also ensures that organizations can quickly spot, and stop, any irregularities.
  • BAA-supported platform: Replaces non-HIPAA compliant tracking technologies and centralizes the collection of website visitor data in a platform backed by a Business Associate Agreement (BAA).
  • A safe-by-default approach: Helps eliminate human error by giving users an opt-in approach to data sharing for tools that aren’t HIPAA compliant.
  • Built-in deidentification: Creates an anonymous visitor ID and uses irreversible cryptographic hashing to de-identify data. Analytics platforms use that anonymous ID to create the complete visitor journey without knowing the visitor’s identity.
  • Industry-best marketing integrations: Prevent protected health information from inadvertently being shared with tools that healthcare marketers rely on, like analytics, direct response advertising, and programmatic ads.

“In today’s post-guidance world, many healthcare organizations are pleading for a clear and durable path forward that balances HIPAA compliance and high-performance marketing,” said Steven Fitzsimmons, CEO and co-founder of Freshpaint. “We are giving healthcare organizations the power to take a privacy-first approach to marketing, not just today but in the future as privacy regulations change.”

Freshpaint’s Healthcare Privacy Platform is already used by Baptist Health, Vybe Urgent Care, Boulder Community Health, and other healthcare organizations of all sizes. With Freshpaint’s Healthcare Privacy Platform, the healthcare sector can look forward to a future where digital innovation and patient privacy go hand in hand.

For more information about the platform or to schedule a demo, please visit www.freshpaint.io.

About Freshpaint

Freshpaint helps healthcare marketers unlock high-performance marketing in a HIPAA-compliant way through its Healthcare Privacy Platform. Freshpaint’s privacy-first approach to data sharing allows healthcare marketers to continue to use the most advanced ad, analytics, and personalization tools – without heavy engineering or long implementation times. Freshpaint is backed by leading investors such as Intel Capital and Y Combinator. For more information, visit www.freshpaint.io.

Media Contact

Angela D’Arcy, TaleSplash for Freshpaint, 1 415-987-5081, [email protected], https://www.freshpaint.io/

SOURCE Freshpaint

health and fitness

Veradermics Doses First Patient in a First-in-Human Clinical Trial for VDPHL for the Treatment of Pattern Hair Loss (Androgenetic Alopecia)

Leave a comment


VDPHL is a once-daily non-hormonal oral therapeutic being developed as a treatment for pattern hair loss

NEW HAVEN, Conn., Nov. 7, 2023 /PRNewswire-PRWeb/ — Veradermics Inc., a clinical-stage medical dermatology company with a pipeline of first-in-class product candidates targeting highly prevalent immunologic and dermatologic conditions, today announced it has commenced dosing in a First-in-Human clinical trial of VDPHL, an investigational, proprietary, non-hormonal oral treatment being developed for pattern hair loss.

Pattern hair loss, also known as androgenetic alopecia, is the most common form of hair loss in the world, impacting 50 million men and 30 million women in the U.S. alone. Existing treatments include topical minoxidil, which faces high discontinuation rates, and oral finasteride, which is only FDA-approved for men and can be associated with unwanted sexual side effects. Veradermics’ VDPHL, a non-hormonal oral therapeutic, has the potential to become a preferred treatment approach for both men and women suffering from pattern hair loss.

“Veradermics is extremely excited to take a step towards addressing the pervasive therapeutic challenge associated with treating pattern hair loss,” said Reid Waldman, MD, CEO of Veradermics. “VDPHL is our second proprietary product candidate advanced into clinical trials in 2023, highlighting the company’s steadfast commitment in and progress towards developing treatments for common skin conditions.”

In 2023, Veradermics also announced the initiation of a Phase 2 trial evaluating VDMN, an immunostimulatory dissolvable microarray patch containing Candida Antigen Extract, for the treatment of common warts. Veradermics’ five-asset pipeline also includes product candidates targeting conditions including alopecia areata, atopic dermatitis, and molluscum contagiosum. The company plans to advance multiple additional product candidates into the clinic in 2024.

“The pattern hair loss treatment landscape urgently needs evidence-based solutions,” added Tim Durso, MD, President of Veradermics. “An oral, non-hormonal treatment like VDPHL has the potential to dramatically change the way hair loss is treated. We are thrilled to announce the dosing of our first patient and are optimistic about the potential impact of VDPHL in this therapeutic category.”

About Veradermics:
Veradermics is a clinical-stage biopharmaceutical company led by experts in dermatology, drug development, and pharmaceutical commercialization that is backed by leading investors in biotech. The company’s 5-asset portfolio includes a balance of late-stage and early-stage product candidates targeting highly prevalent immunologic and dermatologic diseases. Founded by dermatologists, Veradermics leverages its front-line clinical experience to identify and advance novel drugs that address specific patient needs and solve pervasive treatment challenges in dermatology practice. Target indications include common warts, alopecia areata, molluscum contagiosum, androgenetic alopecia (pattern hair loss), and atopic dermatitis. For more information, visit http://www.veradermics.com.

Forward-Looking Statements:
This news release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including “believe”, “may” and “will” and similar expressions, are intended to identify forward-looking statements. These forward-looking statements involve substantial risks and uncertainties, including statements that are based on the current expectations and assumptions of Veradermic’s management about VDMN as treatment for patients with skin disease. Various important factors could cause actual results or events to differ materially from those that may be expressed or implied by our forward-looking statements. The forward-looking statements are made as of this date and Veradermics does not undertake any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. 

Media Contact

Reid Waldman, Veradermics, 913-787-6489, [email protected], https://www.veradermics.com/

SOURCE Veradermics

Health

Intelerad Announces New Leadership Appointments, Setting Course for Next Level Growth

Leave a comment


The new executive leadership team members will manage growth and innovation for Intelerad’s global customer base:

Chris Hare, Chief Growth Officer – With 20 years of experience driving revenue growth and executing operations efficiently, Hare has held executive positions at several high-growth healthcare technology companies. Most recently, he served as the chief revenue officer for AlayaCare, a provider of revolutionary cloud-based home health care software, where he led the organization’s commercial functions. Before that, he was the executive vice president of sales for Net Health, a specialized Electronic Health Record and analytics platform, where he led the global sales team through multiple acquisitions and was responsible for operationalizing the sales organization to create a predictable and scalable growth engine.

Stan Opstad, Chief Product Officer – Bringing over 25 years of experience in strategic planning, product management, product marketing and market development, Opstad’s knowledge spans provider and payer markets across clinical and administrative systems, including EHRs, revenue cycle management, patient engagement and analytics. Prior to joining Intelerad, he was the chief product officer of Zipari, a consumer engagement platform built for improving interaction between patients, providers and payers. At Zipari, Opstad oversaw product strategy and innovation that helped drive improved clinical outcomes and provider satisfaction. He was also the senior vice president of product management of ABILITY Network, which was acquired by Inovalon in 2018, where he built a best-in-class product organization to drive product innovation and establish operational rigor for predictable delivery.

Andy Harris, Chief of Staff – Harris has two decades of experience driving transformations across people, process and technology challenges. Before joining Intelerad, Harris held leadership roles at Deloitte, EY, VMware and other private equity-backed technology organizations. He was most recently at Khoros, first as chief of staff to the CEO and then vice president of business development. In those roles, he drove M&A integrations and scale of the partner ecosystem in the Khoros sales and delivery functions.

“It is essential that healthcare providers receive effective, reliable and innovative solutions from us, and we have built a team of leaders that will hold us accountable to that commitment,” said Bazinsky.

Intelerad was founded over two decades ago to democratize access to medical imaging software solutions. It has since grown to serve nearly 2,500 clients worldwide through its industry-leading medical imaging management suite. Beginning November 26 through 29, Intelerad will attend the Radiological Society of North America’s (RSNA) annual meeting in Chicago, Illinois, where the new executive team members look forward to meeting other industry leaders and forging new connections. To meet with Intelerad at the show, visit intelerad.com/rsna-23.

To learn more about Intelerad visit intelerad.com and follow the company on LinkedIn.

About Intelerad
Intelerad is one of the leading providers of medical imaging software and services for the healthcare industry. Headquartered in Raleigh, NC and Montreal, Quebec, Intelerad has over 900 employees located in offices across six countries. Nearly 2,500 healthcare organizations around the world rely on Intelerad products to manage patient data, helping them reduce time and workload while improving patient outcomes. Intelerad’s award-winning enterprise imaging solutions have been recognized globally by KLAS, with Intelerad’s Image Exchange ranked #1 for eight consecutive years. To learn more, visit intelerad.com.

Media Contact

Hollie Barnidge, Alloy on behalf of Intelerad, 855-300-8209, [email protected], https://www.intelerad.com/en/

SOURCE Intelerad

Health

ZOA Energy Launches Revolutionary Five-in-One Pre-Workout Supplement with Setria® Glutathione

Leave a comment


Athletes who want a competitive edge and achieve strength-training results by maintaining the increase in NO production post-workout* are in luck. Research suggests that Setria® Glutathione may support an increase in NO production when combined with L-Citrulline**, which is also contained in ZOA+. This combination may help sustain NO levels which could lead to reduced fatigue and speed recovery time*.

To support high-intensity workouts, the new supplement contains Beta Alanine, Betaine Anhydrous and CON-Cret® Creatine HCL. For focus, L-Tyrosine, Alpha GPC, and Gingko biloba are included in the formulation. All of these premium ingredients complete the five-in-one advanced formula, providing all of the ingredients needed for maximum performance.

Available in three delicious flavors – Fruit Punch, Wild Berry, and Cherry Lime – ZOA+ is NSF Certified for Sport, an elite certification very few products can claim within the fitness-focused industry. This significant certification guarantees athletes and fitness enthusiasts a product of unparalleled quality and safety. Rigorous testing for banned substances and contaminants instills trust and confidence in its reliability.

Formulated by ZOA Energy Co-founder and Chief Innovation Officer, Dave Rienzi, ZOA+ Powder promises a superior fitness experience. This collaboration is championed by Rienzi’s dedicated co-founders and fitness professionals including Dwyane “The Rock” Johnson, Chief Energy Officer; Dany Garcia, Chief Visionary Officer; and John Shulman, Chief Positivity Officer.

According to Rienzi, “This launch represents a remarkable stride for ZOA Energy, as we reshape the standards of excellence in the fitness industry and beyond.”

ZOA+ Powder is available exclusively on ZOAEnergy.com and Amazon.

*The Food and Drug Administration has not evaluated these statements. This product is not intended to diagnose, treat, cure, or prevent any disease.

To learn more about Setria® Glutathione, visit https://SetriaGlutathione.com.

Media interested in setting up an interview with Karen Todd, please contact Giselle Chollett at [email protected] or 917.386.7116.

About Setria
Setria® Glutathione, manufactured by Kyowa Hakko Bio Co., Ltd., is a clinically studied and patented form of glutathione that, when taken orally, has been shown to replenish the body’s reserves, which may be depleted as a result of poor lifestyle choices, stress or natural aging. Called the “master antioxidant,” glutathione helps protect cells in the body from the damaging effects of oxidative stress and toxins. Setria® Glutathione is manufactured through a patented fermentation process to yield high purity and high quality, is non-GMO, vegetarian and allergen-free. For more information, visit http://www.SetriaGlutathione.com.

About Kyowa Hakko USA
Kyowa Hakko USA is the North & South American office of Kyowa Hakko Bio Co. Ltd., an international health ingredients manufacturer and world leader in the development, manufacturing, and marketing of pharmaceuticals, nutraceuticals, and food & beverage products. Kyowa is the maker of branded ingredients, including IMMUSE™ LC-Plasma, Eyemuse™ Lacticaseibacillus paracasei KW3110, Cognizin® Citicoline, Pantesin® Pantethine, Setria® Glutathione, as well as L-Alanyl-L-Glutamine. For more information, visit http://www.kyowa-usa.com.

About ZOA Energy
ZOA Energy is here to activate the world’s potential: giving people the fuel they need to show up as their best selves. Developed by strength and conditioning coach, Dave Rienzi; global icon and businessman, Dwayne Johnson; global entrepreneur and chairwoman, Dany Garcia; and entrepreneur and investor, John Shulman, ZOA is taking the category to new heights. The ZOA portfolio features both better-for-you energy drinks and a pre-workout supplement––all of which are made with high-quality ingredients, natural flavors and colors, and natural caffeine from green tea and green coffee for clean energy. For more information, please visit ZOAEnergy.com.

Media Contact

Maria Stanieich, Kyowa Hakko USA, 5514829968, [email protected], https://setriaglutathione.com

SOURCE Kyowa Hakko USA

Health

Managing (Multiple) Complex Molecules in CDMO Projects, Upcoming Webinar Hosted by Xtalks

Leave a comment


Four experts from ProBioGen, drawing from their daily experience, will share their insights and experiences. They will answer questions such as:

  • What else is needed besides scientific expertise?
  • What roles do technologies like transposase or platform processes play?
  • How important is strong project management and pronounced customer proximity?

Register for this webinar to learn about key success factors for CDMO projects with multiple complex molecules.

Join experts from ProBioGen, Dr. René Brecht, Senior Vice President, Global Head Manufacturing, Science & Technologies; Annika Lubitz, Director Bioassays (CATS), CATS – Cell and Tissue Services; Dr. Thomas Rose, Head of Expression Systems; and Dr. Ellen Hilgenberg, Senior Business Development Manager, for the live webinar on Wednesday, November 22, 2023, at 12pm EST (5pm GMT/UK).

For more information, or to register for this event, visit Managing (Multiple) Complex Molecules in CDMO Projects.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, vkovacevic@xtalks.com

SOURCE Xtalks

Health

How a world-leading healthcare intelligence CRO is transforming the delivery of clinical trials, Upcoming Webinar Hosted by Xtalks

Leave a comment


  •     How ICON approaches AI
  •     ICON’s award-winning AI solutions help identify the best sites the first time, accurately predict post-marketing requirements and rapidly connect key opinion leaders in a given rare disease space
  •     The future of AI in clinical research

Join the featured speakers to learn how ICON is using AI to improve industry processes and help solve problems people didn’t once think possible.

Join experts from ICON, Gerard Quinn, VP, IT Innovation & Informatics; Michael Phillips, Senior Director, Innovation & Informatics; and Gilyana Borlikova, PhD, Manager, Innovation & Informatics, for the live webinar on Monday, November 27, 2023, at 10am EST (4pm CET/EU-Central).

For more information, or to register for this event, visit Artificial Intelligence at ICON: How a world-leading healthcare intelligence CRO is transforming the delivery of clinical trials.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected]

SOURCE Xtalks

Health

Platform Manufacturing Processes for pDNA, mRNA, LNP and Fill/Finish in Clinical mRNA Therapies, Upcoming Webinar Hosted by Xtalks

Leave a comment


In this free webinar, gain insights into the rapidly evolving landscapes of mRNA and cell/gene therapies and the common challenges they share. Attendees will learn how innovative solutions are driving the development, scaling and commercialization of these therapies. The featured speaker will discuss new capacity installations, unique partnering models and the progress towards commercial manufacturing of pDNA, mRNA, LNP and fill/finish. Attendees will learn about the benefits of using optimized/established manufacturing processes. The speaker will share strategies to overcome common challenges in analytical testing of product and product purity.

TORONTO, Nov. 7, 2023 /PRNewswire-PRWeb/ — Discover an informative webinar delving into commercial manufacturing in messenger RNA (mRNA) clinical therapies, new capacity installations and unique partnering models in commercial manufacturing. mRNA and cell/gene therapies represent cutting-edge approaches in the realm of biomedicine, with a focus on innovative disease targeting and treatment. These fields are rapidly evolving, characterized by intricate landscapes, and share common challenges that demand inventive solutions for their development, scaling and eventual commercialization.

In this webinar, the featured speaker will discuss new capacity installations and unique partnering models and provide key updates on their progress toward commercial manufacturing of plasmid DNA (pDNA), mRNA, lipid nanoparticle (LNP) and fill/finish.

At BIOVECTRA, the immense power of flexibility to revolutionize the future of medicine is harnessed. They are advancing unique technologies that leverage their platform and customized manufacturing solutions and are designed to overcome supply chain complexities, capacity constraints and scalability challenges, which are key limitations to success.

Join this webinar to gain insights into commercial manufacturing in mRNA clinical therapies and the challenges and inventive solutions for development, scaling and commercialization.

Join Jessica Madigan, Director Business Development, Nucleic Acid Modalities, BIOVECTRA, for the live webinar on Tuesday, November 21, 2023, at 1pm EST (10am PST).

For more information, or to register for this event, visit Platform Manufacturing Processes for pDNA, mRNA, LNP and Fill/Finish in Clinical mRNA Therapies.

ABOUT XTALKS

Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.

To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/

Media Contact

Vera Kovacevic, Xtalks, +1 (416) 977-6555 x371, [email protected] 

SOURCE Xtalks

Health

Meller Optics Introduces ER:YAG Laser Active Elements that are Offered in Finished and Semi-Finished Configurations

Leave a comment


Available in 11 standard sizes from 3×35 mm to 6×100 mm and custom sizes on request, Meller ER:YAG Laser Active Elements feature diameter tolerances of +0/-0.05 mm and with matting or polishing +0/-0.1 mm, and length tolerances of +0.5/-0.5 mm. Notching, spherical end facing, and coatings are offered.

Meller ER:YAG Laser Active Elements are priced according to configuration and OEM customer requirements. Meller Optics, Inc. will be exhibiting at SPIE Photonics West, 30 January – 1 February 2024, Booth #1739, at the Moscone Center, San Francisco, CA.

For more information contact:

Meller Optics, Inc.
Craig Schweriner, Marketing
120 Corliss St. / P.O. Box 6001
Providence, RI 02940
(800) 821-0180 FAX (401) 331-0519
e-mail: [email protected]
http://www.melleroptics.com

Media Contact

Craig Schwerener, Meller Optics, Inc., (800) 821-0180, [email protected], www.melleroptics.com

SOURCE Meller Optics, Inc.

Health

RevSpring Meets Unique Needs of Small, Rural Healthcare Systems

Leave a comment


Engage IQ is facilitating one connected experience to deliver an unmatched level of personalization—which inspires patients in rural healthcare markets to participate in, and pay for, their healthcare—and empowering providers to offer an overall better patient experience while reducing stress on staff. The platform is particularly relevant for healthcare systems and safety net hospitals in rural markets that frequently face greater barriers than larger counterparts.

These barriers include prohibitive technology costs, staffing constraints and limited IT resources for integration. Stretched front desk staff and a frequent lack of call center support also create strains on patients and staff during pre- and post-care engagement. Engage IQ integrates well with existing EHRs to round out engagement and payment capabilities. Other costs are streamlined—such as the need for multiple bolt-on vendors—to deliver an overall affordable solution that returns positive ROI and a better patient experience.

“End-to-end technology solutions from RevSpring are giving rural healthcare systems all the benefits of innovation enjoyed by much larger health systems in urban markets,” said Scott MacKenzie, CEO at RevSpring. “We are delighted to help smaller independent healthcare systems reap the rewards of connected intake, clinical reminders, and billing and payment systems all working together. Such integration puts smaller rural healthcare providers on a more level playing field in today’s financially stressed healthcare industry.”

Fisher-Titus, an independent rural community healthcare system in northern Ohio, recently discontinued relationships with three disparate vendors by adopting Engage IQ. The not-for-profit healthcare system now has access to RevSpring’s complete solutions for patient payments, revenue cycle management and merchant services. Fisher-Titus also is using essential Engage IQ Pre-Care tools—appointment reminders and digital forms—to make patient intake faster and more accurate, and to reduce no shows.

Since implementing the new solutions in March 2023, Fisher-Titus patient use of the Engage IQ payment portal has increased 46.8%, days to pay has decreased from 13.5 to 10.1 and paper volume use has decreased by 39%. Engage IQ Pre-Care tools have reduced patient no-show rate by 2.8%. Fisher-Titus also has seen an increase in patients adopting payment plans without involving customer service reps in the process.

“Partnering with RevSpring is delivering tremendous benefits to Fisher-Titus and our patients,” said Laura Lay, vice president, Revenue Cycle at Fisher-Titus. “I’m especially pleased to hear how much patients appreciate the ability to choose payment plans entirely in private through the payment portal. This respects their financial circumstances and the desire for privacy in a small rural community where everyone knows each other.”

About RevSpring
RevSpring leads the market in engagement and payment solutions that inspire patients to participate in and pay for their healthcare. The company has built the industry’s most comprehensive and impactful patient engagement suite, spanning the clinical, administrative and financial experience. RevSpring’s OmniChannel communications and payment solutions are backed by behavior analysis, propensity-to-pay scoring, contextual messaging, and user experience best practices. Using proprietary data analytics to tailor the engagement from preservice to post-service to payment, RevSpring improves the patient experience and outcomes for providers, members and patients. To learn more, visit revspringinc.com/healthcare. Follow us on LinkedIn and X (formerly Twitter).

Media Contact

Kristen Jacobsen, RevSpring, 7639235280, [email protected], www.revspringinc.com 

Kellie Kennedy, The Harbinger Group, 3129334903, [email protected], www.theharbingergroup.com 

SOURCE RevSpring